TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01149993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day for 7 days prior to transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day after transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic (mycophenolic acid)
Description: 720mg twice a day after transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (anti-thymocyte globulin)
Description: standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
Study: NCT03020303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 25Mg Tablet
Description: Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
Study: NCT04935034

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
Study: NCT04055220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment by Regorafenib
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment by Placebo
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;
Study: NCT04087018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zimberelimab
Description: zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zimberelimab
Description: zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
Study: NCT02753283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semi-annual saline injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semi-annual saline injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Study: NCT04144569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Combined With Pyrotinib
Description: PD-1 Combined With Pyrotinib
Study: NCT04533919

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of dorsal root ganglia
Study: NCT04090203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boiled Peanut Powder
Description: Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
Study: NCT03299556

Intervention type: OTHER
Intervention: WHT
Description: Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
Study: NCT01508689

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receive Kellogg's Nutri-Grain® cereal bars first
Description: First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receive Kellogg's Nutri-Grain® cereal bars second
Description: First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
Study: NCT03466658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JumpStart Antimicrobial Wound Dressing
Description: A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
Study: NCT00837434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg dose of etanercept by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg dose of adalimumab by subcutaneous injection
Study: NCT02595125

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IUD
Description: copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
Study: NCT06256185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: Resection of esophageal tumor and lymph node dissection
Study: NCT03181022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
Study: NCT01779830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsules
Description: Administered orally as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsules
Description: Administered orally as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803 - Capsules
Description: Administered orally as capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem - Tablets
Description: Administered orally as tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsules
Description: Administered orally as capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Tablets
Description: Administered orally as tablets.
Study: NCT04277975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal post-discharge opioid prescribing
Description: Opioid prescribed all patients opioids 'in case they are needed' prior to surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted post-discharge opioid prescribing
Description: Opioid only if needed after discharge
Study: NCT01082861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Cervarix, HPV vaccin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Cervarix, HPV vaccin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B, HBV vaccin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B, HBV vaccin
Study: NCT00683527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron
Description: Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
Study: NCT03291535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connected-device
Description: This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: This intervention will consist of usual clinical care as determined by the clinical pharmacist.
Study: NCT03297047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combi cast
Description: upper arm or forearm combi cast

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: combi cast
Description: upper arm or forearm combi cast
Study: NCT01349959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02085460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Rebamipide liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Rebamipide liquid
Study: NCT00758017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture 1
Description: Application of individualised acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture 2
Description: Application of standardised acupuncture
Study: NCT01146769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Description: Pelvic floor strengthening exercise
Study: NCT00739921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal swab under endoscopic guidance
Description: After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus.
Study: NCT01615146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded.
Study: NCT01680341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
Study: NCT00169182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: 75 mg/m 2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m 2 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m 2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoro-3-Pyridinecarboxylic Acid
Description: 750 mg/m 2 by 24-hour continuous infusion for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-3-Pyridinecarboxylic Acid
Description: 750 mg/m 2 by 24-hour continuous infusion for 5 days
Study: NCT03727438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Self CBTI
Description: The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
Study: NCT03868423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: 90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04141748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symphonie Aqua SystemTM
Description: a water filled cylinder that can be pressurized around the residual limb to support body weight

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Casting
Description: plaster of Paris or fiberglass bandages are wrapped around the residual limb
Study: NCT01803009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient views NCI CRC RAT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: View presentation regarding current chance of having an advanced adenoma
Study: NCT02546609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu-Met-Sil 0.5
Description: NS-0200 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu-Met-Sil 1.0
Description: NS-200 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu-Met-Sil 1.0
Description: NS-200 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02905461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive text messages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Text messages not about contraception
Study: NCT05177393

Intervention type: OTHER
Intervention: Assessment of patient-reported outcomes (PROs)
Description: Questionnaires will be administered to participants
Study: NCT03136887

Intervention type: DEVICE
Intervention: JOURNEY II XR Total Knee System
Description: JOURNEY II XR Total Knee System
Study: NCT03913455

Intervention type: DRUG
Group type: OTHER
Intervention: Guadecitabine
Description: Guadecitabine 30 mg/m2 subcutaneously Days 1-5

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV Day 5
Study: NCT03614182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical training concurrent with cognitive training
Description: The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical training followed by cognitive training
Description: The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical training without cognitive training
Description: The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
Study: NCT03913715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ostomy Self-Management Training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ostomy Self-Management Training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
Study: NCT02893397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Wear a fitbit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised exercise sessions